上皮主程序员 Grainyhead-like-2 促进干扰素诱导并抑制乳腺癌复发

IF 3.2 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Molecular immunology Pub Date : 2024-04-30 DOI:10.1016/j.molimm.2024.04.012
Ian MacFawn , Joshua Farris , Phillip Pifer , Naira V. Margaryan , Halima Akhter , Lei Wang , Sebastian Dziadowicz , James Denvir , Gangqing Hu , Steven M. Frisch
{"title":"上皮主程序员 Grainyhead-like-2 促进干扰素诱导并抑制乳腺癌复发","authors":"Ian MacFawn ,&nbsp;Joshua Farris ,&nbsp;Phillip Pifer ,&nbsp;Naira V. Margaryan ,&nbsp;Halima Akhter ,&nbsp;Lei Wang ,&nbsp;Sebastian Dziadowicz ,&nbsp;James Denvir ,&nbsp;Gangqing Hu ,&nbsp;Steven M. Frisch","doi":"10.1016/j.molimm.2024.04.012","DOIUrl":null,"url":null,"abstract":"<div><p>Type-I and -III interferons play a central role in immune rejection of pathogens and tumors, thus promoting immunogenicity and suppressing tumor recurrence. Double strand RNA is an important ligand that stimulates tumor immunity via interferon responses. Differentiation of embryonic stem cells to pluripotent epithelial cells activates the interferon response during development, raising the question of whether epithelial vs. mesenchymal gene signatures in cancer potentially regulate the interferon pathway as well. Here, using genomics and signaling approaches, we show that Grainyhead-like-2 (GRHL2), a master programmer of epithelial cell identity, promotes type-I and -III interferon responses to double-strand RNA. GRHL2 enhanced the activation of IRF3 and relA/NF-kB and the expression of IRF1; a functional GRHL2 binding site in the IFNL1 promoter was also identified. Moreover, time to recurrence in breast cancer correlated positively with GRHL2 protein expression, indicating that GRHL2 is a tumor recurrence suppressor, consistent with its enhancement of interferon responses. These observations demonstrate that epithelial cell identity supports interferon responses in the context of cancer.</p></div>","PeriodicalId":18938,"journal":{"name":"Molecular immunology","volume":"170 ","pages":"Pages 156-169"},"PeriodicalIF":3.2000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence\",\"authors\":\"Ian MacFawn ,&nbsp;Joshua Farris ,&nbsp;Phillip Pifer ,&nbsp;Naira V. Margaryan ,&nbsp;Halima Akhter ,&nbsp;Lei Wang ,&nbsp;Sebastian Dziadowicz ,&nbsp;James Denvir ,&nbsp;Gangqing Hu ,&nbsp;Steven M. Frisch\",\"doi\":\"10.1016/j.molimm.2024.04.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Type-I and -III interferons play a central role in immune rejection of pathogens and tumors, thus promoting immunogenicity and suppressing tumor recurrence. Double strand RNA is an important ligand that stimulates tumor immunity via interferon responses. Differentiation of embryonic stem cells to pluripotent epithelial cells activates the interferon response during development, raising the question of whether epithelial vs. mesenchymal gene signatures in cancer potentially regulate the interferon pathway as well. Here, using genomics and signaling approaches, we show that Grainyhead-like-2 (GRHL2), a master programmer of epithelial cell identity, promotes type-I and -III interferon responses to double-strand RNA. GRHL2 enhanced the activation of IRF3 and relA/NF-kB and the expression of IRF1; a functional GRHL2 binding site in the IFNL1 promoter was also identified. Moreover, time to recurrence in breast cancer correlated positively with GRHL2 protein expression, indicating that GRHL2 is a tumor recurrence suppressor, consistent with its enhancement of interferon responses. These observations demonstrate that epithelial cell identity supports interferon responses in the context of cancer.</p></div>\",\"PeriodicalId\":18938,\"journal\":{\"name\":\"Molecular immunology\",\"volume\":\"170 \",\"pages\":\"Pages 156-169\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0161589024000828\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0161589024000828","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Ⅰ型和Ⅲ型干扰素在病原体和肿瘤的免疫排斥中发挥着核心作用,从而促进免疫原性和抑制肿瘤复发。双链 RNA 是通过干扰素反应刺激肿瘤免疫的重要配体。胚胎干细胞分化为多能上皮细胞会在发育过程中激活干扰素反应,这就提出了癌症中上皮与间质基因特征是否也可能调控干扰素通路的问题。在这里,我们利用基因组学和信号转导方法证明,上皮细胞特性的主编程器--Grainyhead-like-2(GRHL2)能促进Ⅰ型和Ⅲ型干扰素对双链RNA的反应。GRHL2增强了IRF3和relA/NF-kB的活化以及IRF1的表达;在IFNL1启动子中还发现了一个功能性GRHL2结合位点。此外,乳腺癌的复发时间与 GRHL2 蛋白表达呈正相关,表明 GRHL2 是一种肿瘤复发抑制因子,这与它增强干扰素反应的作用是一致的。这些观察结果表明,上皮细胞特性支持癌症中的干扰素反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence

Type-I and -III interferons play a central role in immune rejection of pathogens and tumors, thus promoting immunogenicity and suppressing tumor recurrence. Double strand RNA is an important ligand that stimulates tumor immunity via interferon responses. Differentiation of embryonic stem cells to pluripotent epithelial cells activates the interferon response during development, raising the question of whether epithelial vs. mesenchymal gene signatures in cancer potentially regulate the interferon pathway as well. Here, using genomics and signaling approaches, we show that Grainyhead-like-2 (GRHL2), a master programmer of epithelial cell identity, promotes type-I and -III interferon responses to double-strand RNA. GRHL2 enhanced the activation of IRF3 and relA/NF-kB and the expression of IRF1; a functional GRHL2 binding site in the IFNL1 promoter was also identified. Moreover, time to recurrence in breast cancer correlated positively with GRHL2 protein expression, indicating that GRHL2 is a tumor recurrence suppressor, consistent with its enhancement of interferon responses. These observations demonstrate that epithelial cell identity supports interferon responses in the context of cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular immunology
Molecular immunology 医学-免疫学
CiteScore
6.90
自引率
2.80%
发文量
324
审稿时长
50 days
期刊介绍: Molecular Immunology publishes original articles, reviews and commentaries on all areas of immunology, with a particular focus on description of cellular, biochemical or genetic mechanisms underlying immunological phenomena. Studies on all model organisms, from invertebrates to humans, are suitable. Examples include, but are not restricted to: Infection, autoimmunity, transplantation, immunodeficiencies, inflammation and tumor immunology Mechanisms of induction, regulation and termination of innate and adaptive immunity Intercellular communication, cooperation and regulation Intracellular mechanisms of immunity (endocytosis, protein trafficking, pathogen recognition, antigen presentation, etc) Mechanisms of action of the cells and molecules of the immune system Structural analysis Development of the immune system Comparative immunology and evolution of the immune system "Omics" studies and bioinformatics Vaccines, biotechnology and therapeutic manipulation of the immune system (therapeutic antibodies, cytokines, cellular therapies, etc) Technical developments.
期刊最新文献
Gastric cancer mesenchymal stem cells upregulate PD-1 expression on the CD8+ T cells by regulating the PI3K/AKT pathway. Immunological characteristics of peripheral T cells as prognostic markers for Camrelizumab and Apatinib combination therapy in advanced squamous non-small-cell lung cancer. Silibinin, a PLC-β3 inhibitor, inhibits mast cell activation and alleviates OVA-induced asthma. Genetically engineered bacteria expressing IL-34 alleviate DSS-induced experimental colitis by promoting tight junction protein expression in intestinal mucosal epithelial cells. Screening for immunodominant epitopes of SARS-CoV-2 based on CD8+ T cell responses from individuals with HLA-A homozygous alleles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1